The prognostic and predictive value of ERCC-1, p53, bcl-2 and bax in epithelial ovarian cancer

European Journal of Gynaecological Oncology

Volumn 32, Issue 5, 2011, Pages 516-520

  Avraam, K ^a   Pavlakis, K ^a   Papadimitriou, C ^a   Vrekoussis, T ^b   Panoskaltsis, T ^c   Messini, I ^c   Patsouris, E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c IASO   (Greece)

Author keywords

Bax; Bcl 2; ERCC 1; Ovarian cancer; p53

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PLATINUM DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CLEAR CELL CARCINOMA; CORRELATION ANALYSIS; DISEASE FREE INTERVAL; ENDOMETRIOID CARCINOMA; EPITHELIAL OVARY CANCER; FEMALE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY SEROUS CARCINOMA; PREDICTIVE VALUE; PROGNOSIS; PROTEIN EXPRESSION; TISSUE SECTION; TREATMENT RESPONSE;

ADENOCARCINOMA, CLEAR CELL; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, ENDOMETRIOID; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 81255154092     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J.: "Cancer statistics, 2009". CA Cancer J. Clin., 2009, 59, 225.
2. Leitao M.M. Jr., Chi D.S.: "Operative management of primary epithelial ovarian cancer". Curr. Oncol. Rep., 2007, 9, 478.
3. Gonzalez-Martin A., Toledo G., Chiva L.: "Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting". Clin. Trans. Oncol., 2010, 12, 418.
4. Li Q., Yu J.J., Mu C., Yunmbam M.K., Slavsky D., Cross C.L. et al.: "Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells". Anticancer Res., 2000, 20, 645.
5. Niedernhofer L.J., Odijk H., Budzowska M., van Drunen E., Maas A., Theil A.F. et al.: "The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks". Mol. Cell. Biol., 2004, 24, 5776.
6. Skirnisdottir I., Seidal T., Gerdin E., Sorbe B.: "The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy". Int. J. Gynecol. Cancer, 2002, 12, 265.
7. Kurman R.J., Shih IeM.: "The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory". Am. J. Surg. Pathol., 2010, 34, 433.
8. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V. et al.: "DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy". N. Engl. J. Med., 2006, 355, 983.
9. Kim D.Y., Cho M.S., J.Y. C., Lee E., Mun Y.C., Im S. et al.: "Significance of ercc1 protein expression in predicting response for advanced gastric cancer patients receiving cisplatin containing chemotherapy". Proc. Am. Soc. Clin. Oncol., 2003, 22 (abstr. 1079).
10. Kim M.K., Cho K.J., Kwon G.Y., Park S.I., Kim Y.H., Kim J.H. et al.: "Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy". Clin. Cancer Res., 2008, 14, 4225.
11. Sun Y., Li T., Ma K., Tian Z., Zhu Y., Chen F., Hu G.: "The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells". Cancer Invest., 2009, 27, 891.
12. Leitao M.M., Soslow R.A., Baergen R.N., Olvera N., Arroyo C., Boyd J.: "Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma". Gynecol. Oncol., 2004, 93, 301.
13. Geisler J.P., Geisler H.E., Miller G.A., Wiemann M.C., Zhou Z., Crabtree W.: "p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months". Gynecol. Oncol., 2000, 77, 278.
14. Ziolkowska-Seta I., Madry R., Kraszewska E., Szymanska T., Timorek A., Rembiszewska A., Kupryjanczyk J.: "TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens". Gynecol. Oncol., 2009, 112, 179.
15. Beale P.J., Rogers P., Boxall F., Sharp S.Y., Kelland L.R.: "BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma". Br. J. Cancer, 2000, 82, 436.
16. Kobel M., Kalloger S.E., Boyd N., McKinney S., Mehl E., Palmer C. et al.: "Ovarian carcinoma subtypes are different diseases: implications for biomarker studies". PLoS Med., 2008, 5, e232.